56
https://pubmed.ncbi.nlm.nih.gov/38117458
Dapagliflozin use in a patient with autosomal-dominant polycystic kidney disease resulted in kidney enlargement and decreased kidney function over one year.
Dapagliflozin use in autosomal-dominant polycystic kidney disease leads to kidney enlargement and decreased function.
